World Library  
Flag as Inappropriate
Email this Article

Hidradenitis suppurativa

Article Id: WHEBN0000578144
Reproduction Date:

Title: Hidradenitis suppurativa  
Author: World Heritage Encyclopedia
Language: English
Subject: Hidradenitis, TNF inhibitor, Antiandrogen, Cellulitis, List of cutaneous conditions
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Hidradenitis suppurativa

Hidradenitis suppurativa
Classification and external resources
Specialty Dermatology
ICD-10 L73.2
ICD-9-CM 705.83
DiseasesDB 5892
eMedicine emerg/259 med/2717 derm/892
MeSH D017497

Hidradenitis suppurativa (HS) is a common (though rarely diagnosed), chronic skin disease characterized by clusters of abscesses or subcutaneous boil-like "infections" (oftentimes free of actual bacteria) that most commonly affects apocrine sweat gland bearing areas, such as the underarms, under the breasts, inner thighs, groin and buttocks.[1] The disease is not contagious. There are indications that it is hereditary among certain ethnic groups and autoimmune in nature. Onset is most common in the late teens and early 20's.

HS outbreaks are painful in tender areas and may persist for years with interspersed periods of inflammation, often culminating in sudden drainage of pus. This process often forms open wounds that will not heal and frequently leads to significant scarring. For unknown reasons, people with HS develop plugging of their apocrine glands.[2] Incision and drainage procedures may provide symptomatic relief.

HS flares may be triggered by emotional/erotic stress, sweating, hormonal changes, heat and humidity, and the condition is exacerbated by friction from clothing.

Persistent lesions may lead to the formation of sinus tracts, or tunnels connecting the abscesses or infections under the skin.[3] At this stage, complete healing is usually not possible, and progression is variable, with some experiencing remission for months to years at a time, while others may worsen and require multiple surgeries. Bacterial infections and cellulitis (deep tissue inflammation) are other common complications of HS. Depression and physical pain are often seen with HS and can be difficult to manage.[4]

HS often goes undiagnosed for years due to embarrassment causing delay in seeking treatment. Due to the "invisible" nature of it, it is frequently misdiagnosed.[4] There is currently no known cure nor any consistently effective treatment. HS forums offer great insight.

Carbon dioxide laser surgery has been shown as an effective treatment providing quality of life improvement, with peer reviewed articles showing an 80% chance of non recurrence in the surgically removed site.

Lukewarm Sitz baths can provide great relief, gentle antiseptic skin cleansers and hydrogen peroxide assist in keeping affected areas free of bacteria.

HS is an orphan disease due to lack of publicity and sparse research efforts. The incidence of HS is not well established, but has been estimated as being between 1:24 (4.1%) and 1:600 (0.2%).[5]

Contents

  • Causes 1
    • Triggering factors 1.1
    • Predisposing factors 1.2
  • Stages 2
    • Hurley's staging system 2.1
    • Sartorious staging system 2.2
  • Treatments 3
    • Lifestyle 3.1
    • Medication 3.2
    • Radiation 3.3
    • Surgery 3.4
    • Laser hair removal 3.5
  • Prognosis 4
    • Potential complications 4.1
  • History 5
    • Other names 5.1
    • Histology 5.2
  • References 6
  • External links 7

Causes

The cause of HS remains unknown and experts disagree over proposed causes.[6]

Lesions occur in any body areas with hair follicle although intertriginous areas such as the axilla, groin, and perianal region are more commonly involved. This theory includes most of the following potentials indicators:[7]

The historical understanding of the disease suggests dysfunctional apocrine glands[11] or dysfunctional hair follicles,[12] possibly triggered by a blocked gland, create inflammation, pain, and a swollen lesion.

Triggering factors

There are several triggering factors that should be taken into consideration.

Predisposing factors

Stages

HS presents itself in three stages.[4][11] Due to the large spectrum of clinical severity and the severe impact on quality of life, a reliable method for evaluating HS severity is needed.

Hurley's staging system

This is historically the first classification system proposed, and is still in use for the classification of patients with skin/dermatologic diseases (i.e., psoriasis, HS, acne). Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses. It has been used as a basis for clinical trials in the past and is a useful basis to approach therapy for patients. These three stages are based on Hurley's staging system, which is simple and relies on the subjective extent of the diseased tissue the patient has. Hurley's three stages of hidradenitis suppurativa are as follows:[22]
Stage Characteristics
I Solitary or multiple isolated abscess formation without scarring or sinus tracts. (A few minor sites with rare inflammation; may be mistaken for acne.)
II Recurrent abscesses, single or multiple widely separated lesions, with sinus tract formation. (Frequent inflammation restrict movement and may require minor surgery such as incision and drainage.)
III Diffuse or broad involvement across a regional area with multiple interconnected sinus tracts and abscesses. (Inflammation of sites to the size of golf balls, or sometimes baseballs; scarring develops, including subcutaneous tracts of infection – see fistula. Obviously, patients at this stage may be unable to function.)

Sartorious staging system

The Sartorious staging system is more sophisticated than Hurley's. Sartorius et al. suggested that the Hurley system is not sophisticated enough to assess treatment effects in clinical trials during research. This classification allows for better dynamic monitoring of the disease severity in individual patients. The elements of this staging system are the following:[23]

  • Anatomic regions involved (axilla, groin gluteal or other region or infra-mammary region left or right)
  • Number and types of lesions involved (abscesses, nodules, fistulas, scars, points for lesions of all regions involved)
  • The distance between lesions, in particular the longest distance between two relevant lesions (i.e., nodules and fistulas in each region or size if only one lesion present)
  • The presence of normal skin in between lesions (i.e., are all lesions clearly separated by normal skin?)

Points are accumulated in each of the above categories, and added to give both a regional and total score. In addition, the authors recommend adding a visual analog scale for pain or using the dermatology life quality index (DLQI, or the Skindex) when assessing HS.[24]

Treatments

Treatments may vary depending upon presentation and severity of the disease. Due to the poorly studied nature of this disease, the effectiveness of the drugs and therapies listed below is unclear, and patients should discuss all options with their physician or dermatologist. Nearly a quarter of patients state that nothing relieves their symptoms.[25] Possible treatments include the following:

Lifestyle

  • Changes in diet avoiding inflammatory foods.
  • Warm compresses with distilled vinegar water, and taking hot baths with distilled white vinegar in the water[26] hydrotherapy, balneotherapy.
  • Icing the inflamed area daily until pain reduction is noticed.

Medication

  • Antibiotics- taken orally, these are used for their anti-inflammatory properties rather than to treat infection. Most effective is a combination of rifampicin and clindamycin given concurrently for 2–3 months. This brings about remission in around three quarters of cases.[27] A few popular antibiotics used to treat hidradenitis suppurativa include tetracycline, minocycline, and clindamycin.[28]
  • Corticosteroid injections. Also known as intralesional steroids: can be particularly useful for localized disease, if the drug can be prevented from escaping via the sinuses.
  • Vitamin A supplementation
  • Anti-androgen therapy: hormonal therapy with cyproterone acetate and ethinyl estradiol proved effective in randomized, controlled trials. Dosages reported have been very high.[29]
  • Intravenous or subcutaneous infusion of anti-inflammatory (anti-TNF-alpha) drugs such as infliximab (Remicade), and etanercept (Enbrel),.[30] This use of these drugs is not currently Food and Drug Administration (FDA) approved and is somewhat controversial, and therefore may not be covered by insurance.
  • TNF inhibitor: Studies have supported that various TNF inhibitors have a positive effect on hidradenitis suppurativa lesions.[31] There is a large efficacy and safety study of adalimumab registered with the FDA. It recruited 309 patients and is currently completed. The results have not yet been published. FDA cleared Adalimumab for the treatment for Hidradenitis suppurativa.[32] Humira adalimumab [33] is the first FDA approved drug for the treatment of HS. https://www.humiraforhs.com/?cid=ppc_ppd_ggl_hs_brand_2015_humira_for_hidradenitis_Exact_65U1800902
  • Zinc gluconate taken orally has been shown to induce remission.[34]
  • Chlorhexidine (Hibiclens) plus an antibiotic soap for cleansing the skin surface. Covering sores with Metrolotion after medicated showers. These are considered to be general measures and are the foundation of any good medical treatment and management plan for hidradenitis suppurativa.
  • Topical clindamycin has been shown to have an effect in double-blind placebo controlled studies.[35]
  • Topical resorcinol is a keratolytic agent that targets the follicular keratin plug and has been shown to have efficacy in several case series studies.[36]
  • Topical isotretinoin is usually ineffective in people with HS and is more commonly known as a medication for the treatment of acne vulgaris. Individuals affected by HS who responded to isotretinoin treatment tended to have milder cases of the condition.[37]

Radiation

Electron beam radiotherapy has been a successful treatment of hidradenitis, especially in Europe; it is not a common treatment option in most of the United States, as radiation oncologists generally are disinclined to treating patients with non-malignant diseases because of the potential for secondary radiation-induced tumors in the long term.

Surgery

When the process becomes chronic, wide surgical excision is the procedure of choice. Wounds in the affected area do not heal by secondary intention, and immediate application of a split thickness skin graft is more appropriate.[7]

Laser hair removal

The 1064 nanometer wavelength laser for hair removal aids in the treatment of HS.[38] A randomized control study has shown improvement in HS lesions with the use of an Nd:YAG laser.[39]

Prognosis

In stage III disease, fistulas left undiscovered, undiagnosed, or untreated, can lead to the development of squamous cell carcinoma, a rare cancer, in the anus or other affected areas.[40][41] Other stage III chronic sequelae may also include anemia, multilocalized infections, amyloidosis, and arthropathy. Stage III complications have been known to lead to death, but clinical data is still uncertain.

Potential complications

History

  • In 1839, Velpeau identified and described hidradenitis suppurativa.[48]
  • In 1854, Verneuil described hidradenitis suppurativa as "Hidrosadénite Phlegmoneuse". This is how HS obtained its alternate name "Verneuil's disease".[49]
  • In 1922, Schiefferdecker hypothesized a pathogenic link between "Acne inversa" and human apocrine sweat glands.[50]
  • In 1956, Pillsbury wrote and published a medical journal article discussing hidradenitis suppurativa, describing the disease's main characteristics, dubbing them the "Acne triad: hidradenitis suppurativa, perifolliculitis capitis abscedens et suffodiens".[51] Pillsbury's research study was one of the first peer-reviewed journal articles to appear publicly with many details of hidradenitis suppurativa, which are still used and relied on today in the medical realm of research on this disease.
  • In 1975, Plewig and Kligman, following Pillsbury's research path, modified the "Acne triad", replacing it with the "Acne tetrad: acne triad, plus pilonidal sinus".[52] Plewig and Kligman's research follows in Pillsbury's footsteps, offering explanations of the symptoms associated with hidradenitis suppurativa.
  • In 1989, Plewig and Steger's research led them to rename hidradenitis suppurativa, calling it "Acne Inversa" – which is not still used today in medical terminology; although some individuals still use this outdated term.[53]

A surgeon from Paris, Velpeau described an unusual inflammatory process with formation of superficial axillary, sub-mammary and perianal abscesses in 1839. One of his colleagues also located in Paris, named Verneuil, coined the term “hidrosadénite phlegmoneuse” approximately 15 years later. This name for the disease reflects the former pathogenetic model of acne inversa, which is considered inflammation of sweat glands as the primary cause of hidradenitis suppurativa. In 1922 Schiefferdecker suspected a pathogenicassociation between acne inversa and apocrine sweat glands. In 1956 Pillsbury postulated follicular occlusion as the cause of acne inversa, which they grouped together with acne conglobata and perifolliculitis capitis abscendens et suffodiens (dissecting cellulitis of the scalp) as the "acne triad". Plewig and Kligman added another element to their acne triad, pilonidal sinus. Plewig et al. noted that this new "acne tetrad" includes all the elements found in the original "acne triad", in addition to a fourth element, pilonidal sinus. In 1989, Plewig and Steger introduced the term "acne inversa", indicating a follicular source of the disease and replacing older terms such as "Verneuil disease".

Author Year Findings
Velpeau 1839 First description of the hidradenitis suppurativa
Verneuil 1854 "Hidrosadénite phlegmoneuse"
Pillsbury 1956 Acne triad (hidradenitis suppurativa, perifolliculitis capitis abscendens et suffodiens, acne congoblata)
Plewig & Kligman 1975 Acne tetrad (acne triad + pilonidal sinus)
Plewig & Steger 1989 Acne inversa

Other names

Hidradenitis suppurativa has been referred to by multiple names in the literature, as well as in various cultures. Some of these are also used to describe different diseases, or specific instances of this disease.[4]

  • Acne conglobata – not really a synonym – this is a similar process but in classic acne areas of chest and back
  • Acne Inversa (AI) – a proposed new term[54][55] which has not gained widespread favor.[56]
  • Apocrine acne – an outdated term based on the disproven concept that apocrine glands are primarily involved, though many do suffer with apocrine gland infection
  • Apocrinitis – another outdate term based on the same thesis
  • Fox-den disease – a term not used in medical literature, based on the deep fox den / burrow – like sinuses
  • Hidradenitis Supportiva – a misspelling
  • Pyodermia fistulans significa – now considered archaic
  • Velpeau's disease – commemorating the surgeon who first described the disease in 1833
  • Verneuil's disease – recognizing the surgeon whose name is most often associated with the disorder as a result of his 1854–1865 studies[57]

Histology

Author Year Major Features
Plewig & Steger[53] 1989 Initial hyperkeratosis of the follicular infundibulum. Bacterial super-infection and follicle rupture. Granulomatous inflammatory reaction of the connective tissue. Apocrine and eccrine sweat glands secondarily involved.
Yu & Cook[58] 1990 Cysts and sinus tracts lined with epithelium, in part with hair shafts. Inflammation of apocrine sweat glands only if eccrine sweat glands and hair follicles are also inflamed.
Boer & Weltevreden[59] 1996 Primary inflammation of the follicular infundibulum. Apocrine sweat glands are secondarily involved.

References

  1. ^
  2. ^
  3. ^
  4. ^ a b c d
  5. ^
  6. ^
  7. ^ a b Schawartz's principles of surgery, 8th edition, self assessment an board review, chapter 15, the skin and subcutaneous tissue, question 16
  8. ^
  9. ^ Clinical trial number NCT00329823 for "Etanercept in Hidradenitis Suppurativa" at ClinicalTrials.gov
  10. ^
  11. ^ a b DermNet acne/hidradenitis-suppurativa
  12. ^
  13. ^ a b
  14. ^ a b Jemec GBE. Body weight in hidradenitis suppurativa. In: Marks R, Plewig G, editors. Acne and Related disorders. London: Martin Dunitz; 1989. pp. 375–6.
  15. ^
  16. ^
  17. ^
  18. ^
  19. ^ Hidradenitis Suppurativa at eMedicine
  20. ^
  21. ^
  22. ^ Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. Marcel Dekker, New York, 1989, pp. 729–739.
  23. ^
  24. ^
  25. ^
  26. ^
  27. ^
  28. ^
  29. ^
  30. ^
  31. ^
  32. ^ Clinical trial number NCT01468207 for "Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER I)" at ClinicalTrials.gov
  33. ^
  34. ^
  35. ^
  36. ^
  37. ^
  38. ^
  39. ^
  40. ^
  41. ^
  42. ^ Hurley HJJ. Apocrine glands. New York: McGraw Hill; 1979.
  43. ^
  44. ^
  45. ^
  46. ^
  47. ^
  48. ^ Velpeau A. Aissele. In: Bechet Jeune Z: Dictionnaire de médecine, on Repertoire Générale des Sciences Medicals sous le Rapport Theorique et Pratique. 1839.
  49. ^
  50. ^
  51. ^
  52. ^
  53. ^ a b
  54. ^
  55. ^
  56. ^
  57. ^
  58. ^
  59. ^

External links

  • The Hidradenitis Suppurativa Trust The HS Trust is a UK registered charity
  • Medline: What is Hidradenitis Suppurativa?
  • The Doctor's Doctor
  • Hidradenitis Suppurativa (2004) Prof J. Revuz
  • Hidradenitis Suppurativa Support Hidradenitis Suppurativa Support provides support and advice for sufferers
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.